OW
OWCP.US OWC Pharmaceutical Research Corp
- Market cap
- USD 4.97K
- P/E
- -
- P/B
- 42.29x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is OWCP.US undervalued?
Graham numberThe Graham number of OWC Pharmaceutical Research Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OWC Pharmaceutical Research Corp fundamental analysis
No fundamental analysis for OWC Pharmaceutical Research Corp yet.
OWC Pharmaceutical Research Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to…
Full company profileOWC Pharmaceutical Research Corp financial statements
OWC Pharmaceutical Research Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 50.0K | 0.00 | 0.00 | - | - | - | - |
| Gross Profit | 0.00 | 0.00 | -9.12K | 40.3K | -8.00K | -7.00K | - | - | - | - |
| Operating Income | -231K | -5.03M | -1.65M | -2.10M | -4.55M | -4.30M | - | - | - | - |
| EBITDA | -231K | -5.03M | -1.64M | -2.09M | -4.55M | -3.56M | - | - | - | - |
| Net Income | -318K | -5.07M | -1.65M | -2.29M | -4.56M | -10.3M | - | - | - | - |
| EPS | -0.02 | -0.10 | -0.02 | -0.02 | -0.03 | -0.07 | - | - | - | - |
| Balance Sheet | ||||||||||
| Total Assets | 2.47K | 1.52M | 430K | 497K | 1.06M | 3.55M | - | - | - | - |
| Total Liabilities | 128K | 60.3K | 108K | 396K | 270K | 13.0M | - | - | - | - |
| Shareholders' Equity | -126K | 1.46M | 323K | 101K | 791K | -9.44M | - | - | - | - |
| Cash & Short-term Investments | 2.47K | 1.47M | 357K | 472K | 971K | 3.46M | - | - | - | - |
| Total Debt | 81.9K | - | 3.07K | 250K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -91.8K | -602K | -1.22M | -529K | -1.19M | -2.50M | - | - | - | - |
| Capital Expenditure | 32.2K | 32.2K | 2.57K | 1.86K | 9.51K | 28.0K | 0.00 | - | - | - |
| Free Cash Flow | -91.8K | -635K | -1.22M | -531K | -1.20M | -2.53M | - | - | - | - |
| Ratios | ||||||||||
| ROE | - | -346.7% | -512.7% | -2,265.0% | -576.6% | - | - | - | - | - |
| ROA | -12,892.3% | -333.0% | -384.5% | -460.4% | -429.6% | -288.7% | - | - | - | - |
| Net Profit Margin | - | - | - | -4,574.7% | - | - | - | - | - | - |
| Debt to Equity | - | - | 0.01x | 2.48x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
OWC Pharmaceutical Research Corp dividends
OWC Pharmaceutical Research Corp has not paid dividends in the last 10 fiscal years.
Last stock split: 1:100 on Oct 26, 2012.
Who owns OWC Pharmaceutical Research Corp
Ownership data of OWC Pharmaceutical Research Corp is not available yet.
OWC Pharmaceutical Research Corp company profile
- Company name
- OWC Pharmaceutical Research Corp
- Ticker
- OWCP.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9
- Fiscal year end
- December
- Address
- 2 Ben Gurion Street, Ramat Gan, Israel, 5257334
- Phone
- 972 72 260 8004
- Website
- owcpharma.com
About OWC Pharmaceutical Research Corp
OWC Pharmaceutical Research Corp., through its subsidiary, One World Cannabis Ltd., engages in the research and development of cannabis-based medical products. It develops cannabis-based medical products for the treatment of various conditions, including multiple myeloma, psoriasis, post-traumatic stress disorder, chronic pain, and fibromyalgia. The company is also involved in developing cannabis soluble tablet delivery system. In addition, it provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations. The company was formerly known as Dynamic Applications Corp. and changed its name to OWC Pharmaceutical Research Corp. in December 2014. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Ramat Gan, Israel.
OWC Pharmaceutical Research Corp management
6- Mr. Alon SinaiChief Operating Officer · born 1967
- Dr. Yehuda BaruchChief Medical & Regulatory Affairs Officer · born 1957
- Mr. Ziv TurnerChief Executive Officer · born 1972
- Mr. Shmuel De-SabanCFO & Secretary · born 1966
- Dr. Oron Yacoby-Zeevi DVM, Ph.D.Chief Scientific Officer · born 1961
- Prof. Yuval RamotConsultant